Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill

Cerebrovascular Diseases Clinical Trial

Official title: Clinical Study of Yangxue Qingnao Pill in the Treatment of Mild Vascular Cognitive Impairment Without Dementia (VCIND)

Status Completed

Clinical Trial Summary

In this study, the effectiveness of vascular cognitive impairment was compared among the three groups, namely, the xidezhen group, the Yangxue Qingnao pill group and the placebo group

Clinical Trial Description

The risk factors of various cerebrovascular diseases (atherosclerosis, stroke, hypertension, coronary heart disease, atrial fibrillation, dyslipidemia, diabetes mellitus) are both risk factors of Alzheimer's disease and one of the many causes of vascular dementia. There are many manifestations of mental retardation caused by cerebrovascular diseases. The most prominent aspect is cognitive and behavioral impairment, which is characterized by mental retardation, forgetfulness, misunderstanding and poor calculation ability. Yangxue Qingnao pill (z20063808:) is produced by Tianshili Pharmaceutical Group Co., Ltd, And then improve the ability of learning and memory. Some clinical application results show that the drug can significantly improve the cognitive and behavioral ability of patients with ischemic stroke, improve the cognitive function of patients with mild Alzheimer's disease, and improve the quality of life. Therefore, this study mainly compared the effectiveness of treatment of vascular cognitive impairment in three groups, namely, the xidezhen group, the yangxueqingnaowan group and the placebo group. ;

Related Conditions & MeSH terms

• Cerebrovascular Diseases
• Cerebrovascular Disorders
• Cognitive Dysfunction

• NCT number: NCT04958512
• Study type: Interventional
• Source: Peking University Third Hospital
• Status: Completed
• Phase: N/A
• Start date: August 30, 2017
• Completion date: March 31, 2018